We investigated mutations within the presumed Y-5' exonuclease domain of the DNA polymerase from herpes simplex virus type 1. The mutation sites correspond to residues in DNA polymerase I (Escheriehia coli) which bind two metal ions that are required for exonuclease function. To evaluate the effect of the herpesvirus mutations on enzymatic activity, we overexpressed the wild-type DNA polymerase and one mutant enzyme using a baculovirus expression system. Both proteins exhibited DNA polymerase activity after partial purification, but the mutant protein was drastically deficient in exonuclease activity. This finding suggests that the herpesvirus exonuclease may utilize the same metal-ion-mediated mechanism employed by DNA polymerase I. We also attempted to transfer each of the mutations into the herpesvirus genome using a marker rescue protocol. Although wild-type sequences could be transferred readily, recombinant viruses carrying mutant sequences were not recovered. We discuss the possibility that the mutations are lethal and suggest mechanisms by which a deficiency in Y-5' exonuclease might cause loss of viability.
Introduction
Several mechanisms have evolved to prevent mutations during DNA replication. One major mechanism is the editing of errors by Y-5" exonucleases associated with DNA polymerases. These nucleases act by excising Y nucleotides from the DNA primer, preferentially removing mis-matched termini created by mis-insertion events (Echols & Goodman, 1991) . Organisms with nuclease deficiencies exhibit elevated spontaneous mutation rates, indicating that these activities control the production of mutations in vivo (Echols & Goodman, 1991; Muzyczka et al., 1972; Simon et al., 1991; Morrison et al., 1991; Foury & Vanderstraeten, 1992) . This study investigates the editing nuclease from the DNA polymerase of herpes simplex virus type 1 (HSV-1).
The best understood mechanism for an editing nuclease comes from studies of DNA polymerase I (Escherichia col 0. Structural analysis of the Klenow fragment of this enzyme indicates that the exonuclease forms a distinct domain which binds two divalent metal ions. These ions orient the 3' terminus of the primer within the active site, thus facilitating cleavage (Joyce & Steitz, 1987) . Three aspartic acid residues (D-355, D-424 and D-501) are essential for metal binding and for *Author for correspondence, Fax + 1 520 621-3709. exonuclease function. Site-directed changes at these residues result in enzymes which fail to bind one or both ions and are inactive for exonuclease (Derbyshire et al., 1988 (Derbyshire et al., , 1991 .
The HSV-1 DNA polymerase is required for viral replication and belongs to a large family of polymerases which exhibit sequence similarities and common biochemical properties (Blanco et al., 1991) . These polymerases include eukaryotic enzymes, such as DNA polymerases ~, fi and e from Saccharomyces cerevisiae and human cells, and prokaryotic polymerases from bacteriophages T4 and ~b29. The 3'-5' exonuclease regions in these enzymes are indicated by sequence alignments with DNA polymerase I (E. colO and contain three conserved motifs (called Exo I, Exo II and Exo III) surrounding the invariant aspartic acid residues implicated in metal ion co-ordination (Bernad et al., 1989) . Site-directed alterations of these residues in several cases have produced mutant proteins which retain the ability to polymerize but are deficient in exonuclease activity in vitro (Simon et al., 1991 ; Morrison et al., 1991 ; Foury & Vanderstraeten, 1992; Bernad et al., 1989; Soengas et al., 1992; Reha-Krantz et al., 1991; Frey et al., 1993; RehaKrantz & Nonay, 1993) .
A mode/for the functional organization of the HSV-1 polymerase is suggested by sequence alignments and the locations of drug-resistance mutations. A region in the middle of the protein contains the conserved Exo sites and may represent the 3'-5' exonuclease domain.
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The C-terminal end may constitute a polymerization domain and contains three additional conserved sites, which appear to be essential for polymerase activity in several related DNA polymerases (Delarue et al., 1990; Blasco et al., 1992 Blasco et al., , 1993a Blasco et al., , 1993b Dong et al., 1993) . In HSV-1, certain mutations in this region alter the response of the enzyme to nucleotide analogue inhibitors (Gibbs et al., 1988; Hall, 1988; Larder et at., 1987) , suggesting that this region participates in dNTP recognition during polymerization.
The present study describes HSV-1 DNA polymerase mutations in the three Exo regions that appear to be important for 3'-5' exonuclease function based on sequence alignments. A polymerase carrying one of these mutations is deficient in exonuclease activity but retains polymerase activity in vitro. This result supports the prediction that the mutated residue in tlSV-1 is required for exonuclease function and suggests that the mechanism of the HSV-1 exonuclease is similar to the metalion-mediated mechanism found in DNA polymerase I (E. coli). We also show that herpes viruses carrying these mutations cannot be recovered from marker rescue experiments. A possible explanation for this finding is that an intact 3'-5' exonuclease site is required for virus viability.
Methods
Bacteria. Strains (Sambrook et al., 1989 ) DH1 and DH5~ were hosts for plasmid vectors, JM103 and TG1 for M13 bacteriophage vectors, and RZ1032 for M13 vectors containing uracil residues. Plasmid and M 13 DNA were prepared as described (Sambrook et al., 1989) . Cells were transformed with plasmid DNA by protocol II (Sambrook et al., 1989) . To transform with M13 DNA, log-phase cells were suspended in 50mM-CaC12 at 1/2 volume (20min, 4°C), suspended in CaC12 at 1/10 volume in the presence of DNA (40 min, 4 °C), incubated for 2 min at 47 °C, and then plated with log-phase cells to allow plaque formation.
Cloning techniques and DNA sequencing. Restriction fragments were isolated from 1% low-melting agarose gels (Bio-Rad). Excised bands were melted (10 rain, 65 °C) in equal volumes of buffer (10 mMTris-HC1 pH 7"5, 1 mM-EDTA) and the DNA was extracted with phenol and ether. Ligation reactions were conducted as described by Sambrook et al. (1989) in 50mM-Tris HC1 (pH7.6), 10mM-dithiothreitol, 250 lag/ml bovine serum albumin (BSA), plus 10 mMMgCI 2 and 5 mM-ATP (cohesive termini) or 5 mM-MgCI~ and 2.5 mM-ATP (blunt termini). Where required, 5' single-stranded ends of DNA fragments were filled by DNA polymerase I (Klenow fragment) in the presence of 80 txM-dNTPs (60 min, room temperature). Sequencing was carried out with a T7 DNA Sequenase kit, version 2 (United States Biochemical), using single-stranded M13 templates.
In vitro mutagenesis
Site-directed changes were produced in M13 bacteriophage clones. Oligonucleotides carrying specified mutations were annealed to complementary single-stranded phage DNAs. The molecules were replicated and processed to enrich for mutants (method A or B, see below). Progeny viruses were plaque purified and screened for mutations. Each mutation was confirmed by DNA sequencing.
Method A (Kunkel, 1985) . Single-stranded templates contained uracil residues following growth on RZ1032, which lacks uracil Nglycosylase. Templates were replicated so as to incorporate thymine into the new strands. Strands containing uracil were selectively degraded during subsequent transfection of uracil-repair-proficient JM103 cells.
Method B. Mutations were isolated using the RPN 1523 enzyme kit (Amersham). To enrich for mutated molecules, a region of the double-stranded DNA opposite the desired mutation site was removed by nicking the template strand with NciI, digesting the DNA with exonuclease III, filling the gap by new DNA synthesis, and then transfecting TGI bacteria with the resultant molecules.
Insect cells and baculoviruses. Autographa californica nuclear polyhedrosis virus (AcMNPV) was grown in Spodoptera frugiperda (Sf9) cells. Details of cell culture and virus manipulation methods have been described (Summers & Smith, 1987) . Sf9 cells were routinely grown in suspension in ExCell 400 medium (JRH Biosciences). Virus stocks were prepared by incubating infected cells (0.01 p.f.u./cell) for 4~6 days at 27 °C in TNM-FH medium plus 10% fetal calf serum (FCS). Plaque assays (on 60 mm plates) were overlaid with 4 ml of TNM-FH medium supplemented with 10 % FCS and 1.5 % SeaPlaque agarose (FMC BioProducts), incubated for 6-10 days at 27 °C, and then overlaid with 4 ml of medium-agarose containing 0.02 % neutral red to enhance plaque detection. Where appropriate, 150/ag/ml X-Gal was added.
Transfection with baculovirus DNA. A 1 gg sample of AcMNPV DNA (Invitrogen) was mixed with 1 gg of pBlueBac-pol plasmid DNA in 0.75 ml of transfection buffer (25 mM-HEPES, pH 7.1, 140 mMNaC1, 125 mM-CaC12) for 15 min at room temperature. The DNA solution was added to a 60 mm plate containing 3 x l0 s cells and 0.75 ml of Grace's medium plus 10% FCS. The cells were incubated (4 h, 27 °C), washed with ExCell medium, overlaid with 3 ml of medium plus 0.5 % gentamycin, and incubated (27 °C) until signs of infection were seen. Progeny viruses were titred in a plaque assay with X-Gal to detect recombinants (blue plaques). Recombinant viruses were plaque purified until no polyhedra (indicative of wild-type virus contamination) were seen.
Preparation ofbaculo-infeeted cell extracts. SO cells (3 x 10 ~ cells/ml) were resuspended in medium at 1/10 volume, infected with 10-15 p.f.u./cell (1 h, room temperature), resuspended at the original volume, and incubated for 72 h at 27 °C. The cells were then washed in Grace's medium, resuspended in Buffer B (20mM-HEPES pH 7-6, 10 mM-NaHSO3, 0.5 mM-dithiothreitol, 0-5 mM-phenylmethylsulphonyl fluoride, and 2 ~tg/ml each of pepstatin A, leupeptin, antipain, and benzamidine) at 2-5 x 107 cells/ml, and stored at -70 °C. For analysis, extracts were thawed and sonicated at 4 °C.
Partial purification of HSV-1 DNA polymerases. Sonicated extracts were diluted 2-fold with Buffer B containing 3.4 M-NaC1, incubated for 1 h on ice, spun at 26000 r.p.m. (2 h, 4°C) in a 50 Ti rotor, and dialysed against Buffer C (20mM-HEPES pH7.6, 0"5mM-dithiothreitol, 50 mM-NaC1, 1 mM-EDTA) supplemented with 20% glycerol and 0.5 mM-phenylmethylsulphonyl fluoride. Dialysates were subjected to low speed spins and loaded onto phosphoceUulose columns at ~< 8 mg/ml of packed column. Proteins were eluted with a 150~550 mM-NaC1 gradient in Buffer C plus 20 % glycerol. Polymerase peaks were pooled, dialysed against Buffer C plus 60 % glycerol, and stored at -20 °C. Protein concentrations were determined (Bradford, 1976) according to the specifications of the reagent manufacturer (BioRad). Polymerase activity was determined using the revised polymerase assay (see below), from enzyme dilutions which exhibited linear incorporation with incubation time. Fig. 1 . Physical map of the HSV-1 DNA polymerase region and alignment of conserved sites within the presumed 3'-5' exonuclease domain. The polymerase coding sequence is shown in relation to the Exo motifs described in the text. Amino acid sequences from these motifs are shown within the box, along with an alignment to analogous sequences from DNA polymerase I (E. colO. Numbers indicate the left-most residue in each Exo sequence. The underlined aspartic acid residues in D N A polymerase I bind two divalent metal ions which are required for exonuclease function (Derbyshire et al., 1991) . The exol, exo2 and exo3 mutations constructed for the present study are indicated. Relevant restriction sites spanning the HSV-1 polymerase region and three restriction fragments are also shown. The BamHI Q fragment carries all but the 3' end of the DNA polymerase gene and was previously inserted into pBR322 to produce pBRQ (Hall et al., t989) . This plasmid was used in cloning and marker rescue experiments described in the text. The KpnI-SacI fragment was isolated from pBRQ and inserted into M13mpl8 to produce the M13exo clone used to make the exo mutations. SfiLSacI fragments from M13exo clones carrying these mutations were then re-inserted into pBRQ and used for marker rescue experiments. Two additional markers were used in the marker rescue experiments: Aphrl 2, which confers resistance to aphidicolin and PAA (Hall et al., 1989) , and tsC7, which renders the DNA polymerase temperature sensitive. The map location for tsC7 is based on studies by Coen et al. (1984) and on the assumption that the mutation maps within the polymerase coding sequence, D N A polymerase assays. Assay mixtures (100 gl volume) were incubated at 37 °C for 30min, unless otherwise indicated, and contained 50 mM-Tris-HC1 (pH 8.5), 12 mM-MgCI2, 1.2 mMdithiothreitol, 100 FtM-dNTPs ([3H]TTP, 25 c.p.m./pmol), 0.17 mg/ml of salmon sperm DNA, 0.5 mg/ml BSA, 100 mM-(NH~)2SO4, and 1 Ftl of extract. Where indicated, a revised optimized assay was used, containing 1 mM-MgC12, 1 mg/ml of DNA and 50 mM-(NH4)2SO 4. A 90 gl sample from each reaction was mixed with 1 ml of acid-pyro solution (20mM-sodium pyrophosphate, 7% trichloracetic acid, 0.25 mg/ml BSA) for 5 min on ice. The mixture was poured onto G F / C filters pre-soaked in 0.1 M-sodium pyrophosphate. The filters were washed with 1 M-Ha plus 0" 1 M-sodium pyrophosphate and then with ethanol, dried, and counted. Activity was calculated by subtracting counts incorporated when no enzyme was present and then converting this value to enzyme units (1 unit = 10 nmol incorporation in 30 min at 37 °(2).
Exonuclease assays. Assay mixtures (25 gl volume) were incubated at 23 °C and contained 50 mM-Tris-HC1 (pH 8.5), 2 mM-MgClz, 2 mMdithiothreitol, 0"5mg/ml BSA, 50mM-(NH4)2SO4, approximately 5000 c.p.m, of substrate, and 1 gl of extract. The substrate consisted of M 13 bacteriophage DNA which had been linearized by PstI restriction, labelled at the 3" ends with terminal deoxynucleotidyl transferase and [~32P]dCTP (400 Ci/mmol), and then purified through a NENSORB 20 column (NEN Research Products). Following incubation, assays were mixed with 500 gl of acid-pyro solution, incubated for 15 min on ice, and spun at 15000r.p.m, (10min, 4 °C). A 400 gl sample of supernatant was counted in scintillation fluid to determine the acidsoluble radioactivity. Total radioactivity was determined from an unprecipitated sample from each reaction, and the fraction of soluble radioactivity was calculated.
Monkey cells and herpesviruses. HSV-1 viruses (strain KOS) were grown in Vero cells (from African green monkey kidneys) as described (Hall et al., 1984) . Plaque assays were conducted by infecting cell monolayers in 60 mm Petri dishes (1 h, 34 °C) with 1 ml of virus diluted in medium plus 1% calf serum. The virus was then removed and the ceils were covered with 3 ml of medium plus 1% serum and 0-2% human gamma globulin (to inactivate unadsorbed virus). Where indicated, 125 gg/ml of phosphonoacetic acid (PAA) (Abott Laboratories) or 1 lag/ml of aphidicolin (Sigma) were added (Hall et aL, 1989) . Plates were incubated at an appropriate temperature until plaques appeared. Medium was then removed, cells were fixed in 3 % glutaraldehyde, and plaques stained with 2 % methylene blue.
Marker rescue. The marker rescue protocol for HSV-1 has been described (Hall et al., 1989) . Briefly, Vero cells were treated to allow uptake of viral DNA and plasmid DNA which had been digested with BamHI to release viral sequences. Cells were then incubated in medium containing 5 % calf serum at 34 °C (permissive temperature) until uniformly infected (6-9 days). Viruses were harvested and stored at -20 °C.
Results

Isolation of presumed exonuclease mutations
The HSV-1 DNA polymerase contains three regions which align with Exo I, Exo II and Exo III from DNA polymerase I (E. coli) and other polymerases (Fig. 1) were inserted between the BamHI and HindIII sites of the multiple cloning region in pBlueBacIII (Invitrogen) to create pBlueBac-pol, pBlneBacIII is a modified construct of pJVETL-Z (Vialard et al., 1990) . The HSV-1 insert was derived from two HSV-1 clones, pD702 (Dorsky & Crumpacker, 1988) and pBRQ (Hall et al., 1989) , both made from the KOS strain of HSV-1. Relevant restriction sites within the insert are also indicated. Pn (white box) represents the polyhedrin promoter used for expression of the inserted sequence following transfer of this clone into a recombinant baculovirus. To facilitate creation of pBlueBac-pol, two new sites were created within the HSV-1 polymerase coding region: a BamHI site at the 5' end of the gene and a HindIII site at the 3' end. The BamHI site allowed placement of the polymerase ATG codon near the polyhedrin promoter. To create this site, a new NdeI site was first engineered at the ATG codon (see Methods, method A), using an M 13rap9 clone carrying the indicated BamHI-EcoRI fragment from pBRQ. (The dashed line in this fragment represents sequences from pBRQ not present in the pBlueBac-pol vector.) The NdeI site was then used to insert the 5" end of the polymerase gene into M13mpl8 by filling-in the NdeI end and ligating the blunt end to the phage SmaI site. The adjacent BamHI site was then used to move this region of the polymerase gene into pBlueBacIII. The new HindIII site was derived from pUC19 by inserting the indicated SacI KpnI fragment from pD702 into pUC19. The flanking HindIII site in the vector was then used to move the 3' end of the polymerase gene into pBlueBac-pol, pBlueBac-pol was ultimately created in a three-fragment ligation: BamHl-SacI (5' end of the polymerase gene), SacI HindIII (3' end of the polymerase gene) and HindIII-BamHI (pBlueBacIII vector fragment). A pBlueBac-pol derivative carrying the exol-D368A mutation was constructed by replacing the indicated BglII-SacI fragment from pBlueBac-pol with the corresponding mutant fragment from pBRQ.
regions are i m p o r t a n t for activity, we m a d e specific m u t a t i o n s at these residues. Adenine to cytosine changes at nucleotides 1103, 1312 or 1742 resulted in alanine substitutions at aspartic acid residues 368, 471 and 581, respectively. W e called these mutations e x o l -D 3 6 8 A , exo2-D471A and exo3-D581A. A thymine to adenine change at nucleotide 1104 p r o d u c e d a glutamic acid substitution at aspartic acid residue 368 (exol-D368E).
To facilitate construction o f the site-directed mutants, a K p n I -S a c I restriction fragment (Fig. 1) , which spans the Exo region, was isolated and inserted into M 
Expression o f H S V -1 D N A polymerase using baculovirus vectors
To study the effect of the e x o l -D 3 6 8 A m u t a t i o n on enzyme activity, we used a baculovirus ( A c M N P V ) expression system to over-produce the wild-type and m u t a n t polymerases.
To prepare baculoviruses carrying these HSV-1 genes, Sf9 insect cells were co-transfected with baculovirus D N A and the HSV-1 polymerase clone, pBlueBac-pol. Table 1 , polymerase activity was very low in uninfected cell extracts and increased approximately 8-fold in cells infected with wild-type baculovirus, presumably due to the baculovirus-encoded DNA polymerase. Further increases in activity, 6-9-fold above this level, were shown by recombinant baculoviruses carrying the HSV-1 DNA polymerase gene. This additional activity was substantially inhibited by PAA, a specific inhibitor of the HSV-1 polymerase (13-18% residual activity). In contrast, activity from cells infected with wild-type baculovirus was only mildly inhibited (61% activity). Hence, the increased polymerase activity in the recombinant virus infections appears to result largely from expression of the HSV-1 DNA polymerase.
Comparison of polymerase and exonuclease activities in wild-type and exol-D368A polymerases
Based on the phenotypes of similar mutations in other polymerases, we predicted that the exol-D368A mutant protein should be deficient in exonuclease but should retain polymerase activity. To test this prediction, we purified both wild-type and mutant polymerases by phosphocellulose chromatography and compared their enzymatic activities.
The behaviour of the mutant polymerase during purification indicates that it retains polymerase activity and exhibits chromatographic behaviour similar to that of the wild-type. Both enzymes eluted from the columns I" Peak polymerase fractions from the column were pooled and subjected to protein concentration and activity measurements.
at 100 mM-NaC1 (not shown) and were recovered at similar yields (polymerase units/mg) ( Table 2 ). In addition, both enzymes were extremely sensitive to PAA, as expected for HSV-1 polymerases. As shown in Fig. 3 , these polymerases exhibited approximately 10 % activity in the presence of 10 gg/ml PAA and 2-3 % activity in 100 gg/ml. In contrast, the Klenow fragment of DNA polymerase I (E. coli), which is relatively insensitive to PAA, retained 41% activity at 100 Mg/ml. The phosphocellulose column also removed a contaminating polymerase peak (not shown), which eluted at about 350 m~-NaC1 and probably consisted of baculovirus and/or cellular polymerases. This activity was not sensitive to PAA.
We also compared the exonuclease activities of wildtype and mutant polymerases. Activity was measured by the production of acid-soluble products following digestion of DNA carrying 3' labelled single-stranded ends. As shown in Fig. 4 , the wild-type enzyme exhibited substantial nuclease activity, confirming results from other laboratories (Knopf, 1979; Marcy et al., 1990) . In contrast, the exol mutant was drastically deficient in this assay. Assays containing a mixture of wild-type and mutant polymerases retained high levels of activity, indicating that the mutant preparation did not contain an exonuclease inhibitor. Hence, we conclude that the exol residue is required for exonuclease function.
Attempted transfer of the exo mutations into HSV-1 virus
We then tried to incorporate the new mutations into the herpes virus to assess the mutant phenotypes. Our strategy was to use a marker rescue protocol to transfer 100 "r. the mutations from plasmid clones into viral DNA carrying a temperature-sensitivity mutation (tsC7) in the DNA polymerase gene. The plasmids (pBRQ) carry the HSV-1 BamHI Q fragment which includes the wild-type sequence of the tsC7 site (Fig. 1) . Thus, viral DNA which recombines with the appropriate region of the plasmids should produce temperature-resistant progeny. Some of these progeny should also acquire the desired mutation if the recombination event extends across the mutant site.
In several experiments, a second marker, downstream of the Exo sites was also used. This marker, called Aphrl2 ( Fig. 1) , confers resistance to aphidicolin and PAA, two inhibitors of the HSV-1 DNA polymerase (Hall et al., 1989) . In experiments using this marker, most progeny which are both temperature-and drug-resistant should have incorporated the plasmid sequences between the markers and should carry any exo mutations present. The results of marker rescue experiments for each of the exo mutations (exol-D368A, exol-D368E, exo2-D471A and exo3-D581A) are shown in Table 3 . Cells were exposed to tsC7 viral DNA and plasmid DNA, and viral progeny were examined for temperature-and drugresistance. Compared to the controls (without plasmids), the recovery of temperature-or drug-resistant progeny was substantially increased when cloned DNA polymerase sequences were present. Hence, these progeny result from recombination events and not from spontaneous production of tsC7 revertants or drug-resistant progeny.
Plasmids carrying the Aphrl2 marker were used in experiments 1-4 (Table 3) . In each experiment, the presence of wild-type sequences within the Exo region produced recombinants exhibiting temperature-or drugresistance at frequencies typically ~> 0-1% of the progeny and produced recombinants exhibiting both phenotypes at 0.002~).09%. In contrast, experiments involving plasmids with any of the exo mutations showed lower yields of the single-phenotype recombinant classes (usually < 0.1% of the progeny) and failed to produce significant yields of the double-phenotype class (<4x10-~%). These results suggest that the exo mutations interfere with production of recombinant viruses, possibly by preventing viral growth.
To rule out the possibility that a spontaneous but lethal mutation occurred in the original M 13exo clone used to generate the exo mutations, we re-cloned the Exo region (Fig. 1 , SfiI-SacI fragment) from M13exo into a pBRQ plasmid carrying the Aphrl2 mutation (pBRQ Aphrl2-exo + re-clone) and used this plasmid in a marker rescue experiment (Table 3 , experiment 1). A lethal mutation within the re-cloned region should inhibit detection of the double-phenotype recombinant class. However, a significant yield of the double-phenotype class was obtained. Hence, the exo mutations themselves may be lethal to the herpesvirus.
Another possible explanation for our results is that the exo mutations interact with the Aphrl2 mutation, producing an inactive (or drug-sensitive) polymerase. To 
Experiment 4
No plasmid < 0-00029 0.046 < 0.00011 < 0"00009 < 0-00009 Aph~12 0-0053 1.64 0.0019 (100) 0-11 0.0050 (100) Aphq2 exo3-D581A 0"077 0"24 ~< 0.00041 (~< 22) 0.0054 < 0.00003 (< 0.6)
Experiment 5
No plasmid ~< 0.00034
* Vero veils were transfected as described in Methods with tsC7 viral DNA and cloned DNA fragments (BamHI Q) carrying the wild-type sequence corresponding to the temperature-sensitivity locus and, where indicated, exo mutations and/or the Aphrl2 drug-resistance marker. Markers relevant to these experiments are shown in Fig. 1 . Progeny viruses were recovered and assayed in plaque assays at permissive and non-permissive temperatures and in the presence or absence of drugs to determine the temperature-resistant (Ts+), PAA-resistant (Paa r) and aphidicolin-resistant (Aph r) fractions (relative yields are shown in parentheses). Values for experiments 1, 2 and 5 are the average of two or more experiments. Similar results (not shown) were obtained using independently derived exol-D368A, exol-D368E and exo2-D471A clones. t In one experiment with an exo2-D471A clone, a small number of Ts + Aph r plaques were observed. Five plaques were picked and the exo2 region was amplified by PCR. The amplified DNA was then sequenced (data not shown). In all cases, the sequences at the exo2 site were wild-type, suggesting that these plaques were not true Ts + Aph r recombinants but rather were temperature-resistant recombinants which had spontaneously mutated to aphidicolin resistance.
investigate this possibility, we conducted a similar marker rescue experiment with plasmids carrying exol-D368A but lacking the Aphrl2 marker (Table 3 , experiment 5). Temperature-resistant progeny were recovered and analysed for the presence of the mutation by amplifying the Exo I region using PCR and determining the sequence by restriction analysis and/or DNA sequencing (not shown). From previous marker rescue experiments, we predicted that approximately 1/5 of the recombinants should carry both the temperatureresistance and exo markers. However, analysis of 20 isolates from the present experiment failed to reveal any progeny carrying the exo 1 mutation.
Finally, the exonuclease mutations might confer temperature sensitivity, and thus might not be isolated among the temperature-resistant recombinants. We therefore examined the heat-stability of both wild-type and exol-D368A DNA polymerases, as shown in Fig. 5 . The polymerases were incubated at 50 °C for various times and then assayed for polymerase activity at 37 °C.
Mutant and wild-type enzymes showed very similar inactivation profiles. Hence, the mutant is not temperature-sensitive under these conditions.
Discussion
We studied the effects of mutational changes at aspartic acid residues 368,471 and 581 within the presumed 3'-5' exonuclease domain of the HSV-1 DNA polymerase. Regions surrounding these residues can be aligned to sequences within the 3'-5' exonuclease domain of DNA polymerase 1 (E. coli). These alignments indicate a possible correspondence between the HSV-1 residues and three aspartic acid residues in DNA polymerase I which are essential for 3'-5' exonuclease activity and bind two Mg ~+ ions (Joyce & Steitz, 1987) . The Mg 2+ ions appear to co-ordinate binding of the 3'-OH primer terminus and participate in the transition state of the cleavage reaction. Alanine substitutions at these residues in DNA polymerase I produce mutants which lack 3'-5' exonuclease but retain polymerase activity (Derbyshire et al., 1988 (Derbyshire et al., , 1991 . We found that one of the HSV-1 mutations (D368A) also severely inactivates the 3'-5' exonuclease of this enzyme, while not affecting polymerase activity in vitro.
The 3'-5' exonuclease region from DNA polymerase I also aligns with sequences within DNA polymerases more closely related to the HSV-1 polymerase (Bernad et al., 1989) . The three aspartic acid residues are also conserved within this larger group of enzymes. Alanine substitutions at these residues in several enzymes specifically inactivate the 3' 5' exonuclease (Simon et al., 1991; Morrison et al., 1991; Foury & Vanderstraeten, 1992; Bernad et al., 1989; Soengas et al., 1992; RehaKrantz et al., 1991; Frey et al., 1993; Reha-Krantz & Nonay, 1993) . Taken together, these studies fulfil the prediction from the DNA polymerase I model that the three aspartic acid residues are essential for exonuclease activity and suggest that the Mg-mediated mechanism proposed for DNA polymerase I is a general mechanism for 3' 5' exonucleases. Our results extend these findings to the herpes simplex DNA polymerase.
To study the phenotype of exonuclease-deficient herpes simplex viruses, we attempted to transfer the aspartic acid mutations into HSV-1 by marker rescue. However, we were unable to recover recombinant mutant viruses. One possible explanation for our findings is that the mutations are lethal. This possibility is consistent with results in other systems. Reduced viability has been observed in yeast (S. cerevisiae) strains carrying similar mutations in the mitochondrial polymerase (Foury & Vanderstraeten, 1992) and in T4 bacteriophage polymerase mutants (Reha-Krantz et al., 1991; Frey et al., 1993) . In addition, yeast (S. cerevisiae) cells carrying similar mutations in both DNA polymerase 6 and e grow normally as diploids but are inviable in the haploid state (Morrison & Sugino, 1994) . Finally, two other mutations in the exonuclease region of the HSV-1 polymerase are lethal (Gibbs et al., 1991) , although these mutations differ from ours by inactivating the DNA polymerase activity,
We have presented evidence against certain other possibilities which might explain our failure to isolate HSV-1 exonuclease mutants. For example, since our protocol selected for recombinants which are both temperatureand drug-resistant, if all of the mutations conferred temperature-or drug-sensitivity, no mutant recombinants would have been recovered. We think these possibilities are unlikely since such phenotypes would have to result from four mutations at three different sites. In addition, recombinants carrying exo 1-D368A were not recovered, even in the absence of the second drug-resistance selection, and the exol-D368A polymerase did not appear temperature sensitive in a heat-inactivation experiment.
Alternatively, it is possible that the mutations prevent the initial formation of recombinants, perhaps by altering the DNA structure. Again, it seems unlikely that structural effects would occur at three different loci.
How might an intact exonuclease site be required for virus viability? Based on the high level of DNA polymerase activity exhibited by the HSV-1 exol-D368A mutant, we suggest that the potential lethality of our mutations is not due to polymerase inactivation. However, the mutant proteins might be deficient in some aspect of replication in vivo which is not essential in our in vitro assay.
One possibility is that the mutations might interfere with editing by the 3'-5' exonuclease, causing high levels of deleterious mutations. 3'-5' exonuclease deficiencies in DNA polymerases from T4 bacteriophage, E. coli (DNA polymerase III), and yeast (S. cerevisiae) produce elevated mutation rates in vivo (Echols & Goodman, 1991; Muzyczka et al., 1972; Simon et al., 1991; Morrison et al., 1991; Foury & Vanderstraeten, 1992) . Wild-type HSV-1 normally has a high spontaneous mutation rate (Hall et al., 1984) , and further increases due to an editing deficiency might be intolerable.
Alternatively, exonuclease deficiencies might irreversibly block replication at 3' mis-matched termini. Many studies have indicated that DNA polymerases are slow to extend mis-matched termini (Echols & Goodman, 1991) . This phenomenon presumably facilitates transfer of the 3' terminus to the editing site. Experiments with exonuclease-deficient polymerases from bacteriophages T4 and ~b29 have shown that extension of mismatched termini is strongly suppressed when editing cannot occur (Reha-Krantz & Nonay, 1993; Garmendia et al., 1992) . The HSV-1 polymerase might be exceptionally vulnerable to replication inhibition by mismatched primers.
A third possibility is that disruption of the exonuclease site might impair some essential aspect of polymerization (e.g. DNA binding or translocation). The aspartic acid mutations described in this study may affect binding of metal ions, thus altering the polymerase in some global way so as to impair other polymerase functions. These functions might be dispensable in our in vitro assay, which measures repair of short-gapped regions at high enzyme concentrations, but might be essential in vivo, where long stretches of replication occur and the polymerase concentrations are low.
A possible role for the exonuclease site in polymerization is supported by evidence that the exonuclease and polymerase domains of the HSV-I DNA polymerase are functionally inter-connected. This evidence is supplied, in part, by genetic studies. In HSV-1, two mutations from the predicted exonuclease region suppress a drug hypersensitivity mutation in the polymerization domain (Wang et al., 1992) . Two other mutations near the Exo II site are lethal and destroy polymerase activity (Gibbs et al., 1991) . In vaccinia virus (a member of the HSV-1 polymerase family) a mutation in the presumed exonuclease region requires a second, downstream mutation for a full drug-resistant phenotype (Taddie & Traktman, 1993) . Biochemical evidence also supports this model. In HSV-1, PAA and certain antibodies directed against the presumed HSV-1 polymerase domain inactivate both polymerase and exonuclease activities (Ostrander & Cheng, 1980; Knopf, 1979; Knopf & Weisshart, 1990) . Finally, exonuclease deficient polymerases from yeast (S. cerevisiae) mitochondria and bacteriophage ~29 are impaired in their ability to polymerize in vitro, due to translocation or strand-displacement defects (Foury & Vanderstraeten, 1992; Soengas et al., 1992) . This inter-connected model contrasts strikingly with the structure of DNA polymerase I from E. coli, which folds into separate exonuclease and polymerase domains (Ollis et al., 1985) .
The relationship between exonuclease and polymerase domains of the HSV-1 DNA polymerase has important implications for antiviral drug design. Drugs such as acyclovir are nucleotide analogues targeted against the DNA polymerase. Acyclovir is effective because it is phosphorylated by the viral thymidine kinase and then incorporated into viral DNA by the DNA polymerase (Elion et al., 1977) . Its lack of a 3'-OH causes chain termination, and it is resistant to editing by the 3'-5' exonuclease (Derse et al., 1981) . However, drug resistance can occur, especially by mutations which inactivate the viral thymidine kinase. A better understanding of the exonuclease site might allow design of drugs specifically targeted to this site.
In summary, we have found that a mutation at a residue required for editing nuclease function in several polymerases affects the exonuclease of the HSV-1 DNA polymerase. Four mutations in the HSV-1 exonuclease region also interfere with the formation of viable HSV-1 recombinants. We suggest that loss of viability may result from unedited mis-incorporation events or may indicate that an intact exonuclease site is required for polymerization in vivo. Our findings also suggest that design of new drugs targeted against the exonuclease domain of herpes DNA polymerases may be an effective therapeutic strategy.
